MERIDEN, Conn. -- A Meriden biopharmaceutical company has begun manufacturing a vaccine to protect people from the H1N1 flu virus.

The company, Protein Sciences Corp., said the vaccine is called PanBlok.

The vaccine is created using proprietary baculovirus and insect cell manufacturing technology.

PSC officials said they believe the vaccine is the only vaccine that could be used to protect against the escalating worldwide pandemic, at least for the next few months.

Protein Sciences Corp. said it's able to produce 100,000 doses of the vaccine each week.

However, following bulk production, officials said, the vaccine will undergo routine quality tests, the longest of which will require up to one month, officials said. Mid-July, they said, the vaccine should be ready for use in clinical trials and/or for vaccinations in countries that grant regulatory clearance.

"We are in the process of transferring our proprietary manufacturing technology to facilities in other countries and we are setting up a foundation to ensure vaccine availability for U.N. member countries consistent with the commitment we made to the World Health Organization and the United Nations in Geneva, Switzerland on May 19, 2009." Said Daniel Adams, chairman, president and CEO of the company said.

PSC also announced that it will begin shipping H1N1 protein for research use to customers with pre-orders. Orders can be placed on the company's Web site.

PSC is in talks with various parties in the U.S. and abroad to conduct the first human clinical trials of an H1N1 vaccine, officials said. Such studies will evaluate different doses, two dosing regimes and an adjuvanted formulation of the vaccine.